Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pulmonx (LUNG) Research & Development (2019 - 2025)

Historic Research & Development for Pulmonx (LUNG) over the last 7 years, with Q3 2025 value amounting to $4.8 million.

  • Pulmonx's Research & Development rose 2943.38% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.9 million, marking a year-over-year increase of 826.8%. This contributed to the annual value of $17.6 million for FY2024, which is 282.08% down from last year.
  • Pulmonx's Research & Development amounted to $4.8 million in Q3 2025, which was up 2943.38% from $5.3 million recorded in Q2 2025.
  • Over the past 5 years, Pulmonx's Research & Development peaked at $5.7 million during Q2 2023, and registered a low of $2.8 million during Q3 2021.
  • For the 5-year period, Pulmonx's Research & Development averaged around $4.2 million, with its median value being $4.0 million (2024).
  • As far as peak fluctuations go, Pulmonx's Research & Development soared by 14586.26% in 2021, and later plummeted by 1127.96% in 2024.
  • Over the past 5 years, Pulmonx's Research & Development (Quarter) stood at $3.7 million in 2021, then rose by 5.26% to $3.9 million in 2022, then fell by 0.18% to $3.9 million in 2023, then increased by 2.7% to $4.0 million in 2024, then grew by 21.12% to $4.8 million in 2025.
  • Its Research & Development was $4.8 million in Q3 2025, compared to $5.3 million in Q2 2025 and $4.8 million in Q1 2025.